학술논문

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
Document Type
Article
Source
In The Lancet Haematology June 2024 11(6):e436-e447
Subject
Primary Research
Articles
Language
ISSN
2352-3026